Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 10/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.40 |
| ▸ | USP1 | O94782 | 2/20 | 0.39 |
| ▸ | WDR48 | Q8TAF3 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6759306 | 0.84 | BDKRB1 (0.48) | BDKRB1KDRMAPT | |
| SCHEMBL9854331 | 0.78 | CYP1A2 (0.52) | BDKRB1BACE1HDAC1 | |
| SCHEMBL6754038 | 0.77 | BDKRB1 (0.70) | BDKRB1MAPT | |
| SCHEMBL6285864 | 0.77 | BACE1 (0.65) | BACE1MAPT | |
| SCHEMBL31631318 | 0.77 | BACE1 (0.65) | BACE1MAPT | |
| SCHEMBL29957028 | 0.76 | EGFR (0.50) | BACE1KDR | |
| SCHEMBL11016635 | 0.73 | APP (0.54) | BACE1KDRPOLBMAPT | |
| SCHEMBL5212805 | 0.73 | APP (0.54) | BACE1POLBMAPT | |
| SCHEMBL7835214 | 0.73 | KDM4E (0.55) | BACE1KDRPOLBMAPT | |
| SCHEMBL10370951 | 0.73 | CA12 (0.42) | BACE1HDAC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034064-A1 | 2-(biarylalkyl)amino-3-(alkanoylamino)pyridine derivatives | KUDUK SCOTT D (US) | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034064-A1 | 2-(biarylalkyl)amino-3-(alkanoylamino)pyridine derivatives | BDKRB1, BDKRB2, LTB4R2 | BDKRB1 1/4885BACE1 836/4885XDH 3545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.